Abstract 157P
Background
Gastric cancer (GC) is among the most common malignancy worldwide. The UICC/AJCC TNM classification is the most commonly used classification system. For adequate N staging at least 15 lymph nodes should be retrieved. In some countries, this amount of lymph nodes is not met, which can lead to understaging. The phenomenon of stage migration is caused by an insufficient number of lymph nodes examined. In order to reduce stage migration, some investigators have proposed using the metastatic lymph node ratio (LNR), namely the ratio between positive lymph nodes compared with the total number of lymph nodes examined, as a new prognostic indicator for gastric cancer.
Methods
Total 116 patients who underwent upfront D2 gastrectomy between 2012 to 2017 were included. LNR has classified into 4 groups: LNR0; 0, LNR1; >0-0.13; LNR2; 0.14-0.40 and LNR3; 0.41-1. We have used Kaplan-Meier method to calculate survival rates and log rank test to compare survival curves between groups.
Results
Males (58.6%) were more common than females (41.4%). Mean age at presentation was 56.12 years. Most common mode of presentation was pain abdomen (53.8%). Most common location of tumor was distal part (81%). Most commonly done procedure was distal radical gastrectomy (56.9%) followed by subtotal gastrectomy (32.8%). Median number of lymph nodes isolated was 14. 54 patients received adjuvant chemotherapy while 32 patients adjuvant chemoradiation. At a median followup of 14 months (range, 2–78 months), overall 5-year survival was 23.75%. (Median survival: 24 months). The 5-year survival for Stages I–III was 100%, 26.25%, and 11.25%, respectively (P < 0.001). In the univariate analysis; sex (p < 0.05), tumor grade (p < 0.001), T stage (p < 0.001), N stage (p < 0.001), TNM stage (p < 0.001), and LNR (p < 0.001) were statistically significant. The multivariate analysis showed that tumor grade, T stage, N stage, TNM stage and LNR still had statistical significance. In subgroup analysis of patients with less than 15 obtained lymph nodes, LNR was still a significant predictor of survival.
Conclusions
LNR can estimate prognosis of patients who undergo D2 gastrectomy, regardless of the number of lymph nodes examined. Thus LNR may become a new indicator to evaluate prognosis after D2 gastrectomy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract